FGAM
KRTX

Financial Gravity Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Financial Gravity Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-217
Closed -$354 – 1828
2023
Q2 		$354 Buy
+217
New +$46.5K ﹤0.01% 1052

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Financial Gravity Asset Management's KRTX Position: Q3 2023 in Review

Financial Gravity Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 217 shares — an estimated $354 sold.

Financial Gravity Asset Management first reported a position in KRTX in Q2 2023 and held it in 1 quarter. The position peaked at $354 in Q2 2023. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

  • Financial Gravity Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Financial Gravity Asset Management sold 217 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $354.
  • Financial Gravity Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Financial Gravity Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $354 in Q2 2023.
  • 256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Financial Gravity Asset Management's 13F filing for Q3 2023, filed 16 Nov 2023.